Covalent pan-TEAD inhibitors for the treatment of cancers with Hippo pathway alterations. (October 2022) - Guo, S.; Huang, C.; Shrishrimal, S.; Cui, J.; Zhang, V.; Deng, N.; Dong, I.; Wang, G.; Begley, C.G.; Luo, S.; Cao, P.; Wiedemeyer, W.